awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35837560-5089F259-C58C-401E-98B2-B9AEEF98E597
Q35837560-5089F259-C58C-401E-98B2-B9AEEF98E597
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35837560-5089F259-C58C-401E-98B2-B9AEEF98E597
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
P2860
Q35837560-5089F259-C58C-401E-98B2-B9AEEF98E597
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35837560-5089F259-C58C-401E-98B2-B9AEEF98E597
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
086c5b4fb2508a0cbd11758791812a8c148e9c9e
P2860
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.